Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$449K Sell
3,756
-88
-2% -$11.5K 0.15% 90
2025
Q4
$523K Sell
3,844
-22
-0.6% -$3.16K 0.17% 84
2025
Q3
$570K Sell
3,866
-617
-14% -$85.6K 0.2% 76
2025
Q2
$580K Buy
4,483
+427
+11% +$51.7K 0.22% 73
2025
Q1
$485K Sell
4,056
-68
-2% -$8.43K 0.21% 80
2024
Q4
$478K Buy
4,124
+119
+3% +$15K 0.2% 79
2024
Q3
$541K Sell
4,005
-339
-8% -$45.4K 0.23% 74
2024
Q2
$589K Buy
4,344
+3
+0.1% +$408 0.27% 64
2024
Q1
$561K Sell
4,341
-48
-1% -$5.8K 0.27% 65
2023
Q4
$502K Buy
4,389
+3
+0.1% +$299 0.27% 72
2023
Q3
$399K Buy
4,386
+3
+0.1% +$309 0.24% 82
2023
Q2
$494K Buy
4,383
+7
+0.2% +$740 0.29% 69
2023
Q1
$458K Buy
4,376
+9
+0.2% +$940 0.29% 73
2022
Q4
$483K Hold
4,367
0.32% 66
2022
Q3
$483K Buy
+4,367
New +$397K 0.32% 66

Other funds holding XYL

Barrett & Company's XYL Position: Q1 2026 in Review

Barrett & Company reduced its Xylem (XYL) stake by 2.3% in Q1 2026, selling an estimated $11.5K and leaving 3,756 shares worth $449K. The position accounts for 0.15% of the portfolio, ranked #90.

Barrett & Company first reported a position in XYL in Q3 2022 and has held it in 15 quarters since. The position peaked at $589K in Q2 2024. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • Barrett & Company held 3,756 shares of Xylem worth $449K as of Q1 2026.
  • Barrett & Company sold 88 Xylem shares in Q1 2026, an estimated $11.5K.
  • Xylem made up 0.15% of Barrett & Company's portfolio in Q1 2026, its #90 holding.
  • Barrett & Company first reported a position in Xylem in Q3 2022 and has held it in 15 quarters since.
  • Barrett & Company's Xylem position peaked at $589K in Q2 2024.
  • 1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.